Congress targets hidden drug markups: PBMs must disclose pricing or face $1M fines
S. 526 — Pharmacy Benefit Manager Transparency Act of 2025 · Filed by Chuck Grassley (R-IA) · 14 cosponsors · Introduced Feb 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits pharmacy benefit managers (PBMs) from charging health plans more for drugs than they reimburse pharmacies for the same drugs while pocketing the difference, from arbitrarily clawing back pharmacy payments, or from shifting costs to pharmacies to offset federal reimbursement cuts. It requires PBMs to disclose all pricing, fees, and rebates to health plans and pharmacies, report annually to the FTC and HHS, and protects whistleblowers who report violations. The FTC gains enforcement authority with civil penalties up to $1 million per violation.
Why we flagged it
The bill's core mechanism is a transparency and anti-fraud mandate targeting PBM pricing practices, with FTC enforcement. It is regulatory reform aimed at reducing hidden intermediary markups in prescription drug distribution.
What the text implies
- PBMs may respond by consolidating (horizontal or vertical mergers) to achieve scale and offset compliance costs; the bill directs the FTC to study this risk but does not prevent it.
- Disclosure requirements may reveal competitive intelligence (rebate amounts, formulary strategies) that could accelerate industry consolidation or shift negotiating power.
The full analysis lists 5 implications of this text.
Who stands to gain
independent pharmacies (reduced clawbacks, more transparent reimbursement); health plans and employers (lower PBM markups, rebate pass-through); consumers (lower premiums and out-of-pocket costs from reduced intermediary inflation)